These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15648198)

  • 1. Screening for cancer: are resources being used wisely?
    Kaplan RM
    Recent Results Cancer Res; 2005; 166():315-34. PubMed ID: 15648198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of prostate cancer screening.
    Benoit RM; Naslund MJ
    Oncology (Williston Park); 1997 Oct; 11(10):1533-43; discussion 1543, 1547-8. PubMed ID: 9348558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic evaluation of population-based mass screening for the early detection of cancer: a systematic review].
    Muszbek N; Koncz T; V Hajdú P; Adány R
    Magy Onkol; 2002; 46(2):119-29. PubMed ID: 12202891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
    Tscheulin DK; Drevs F
    Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer screening rates in individuals with different life expectancies.
    Royce TJ; Hendrix LH; Stokes WA; Allen IM; Chen RC
    JAMA Intern Med; 2014 Oct; 174(10):1558-65. PubMed ID: 25133746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unanswered questions in screening for prostate cancer.
    Neal DE; Leung HY; Powell PH; Hamdy FC; Donovan JL
    Eur J Cancer; 2000 Jun; 36(10):1316-21. PubMed ID: 10882874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial.
    Diederichsen AC; Rasmussen LM; Søgaard R; Lambrechtsen J; Steffensen FH; Frost L; Egstrup K; Urbonaviciene G; Busk M; Olsen MH; Mickley H; Hallas J; Lindholt JS
    Trials; 2015 Dec; 16():554. PubMed ID: 26637993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer screening and health system resilience: keys to protecting and bolstering preventive services during a financial crisis.
    Martin-Moreno JM; Anttila A; von Karsa L; Alfonso-Sanchez JL; Gorgojo L
    Eur J Cancer; 2012 Sep; 48(14):2212-8. PubMed ID: 22424881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
    Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of cancer screening in end-stage renal disease.
    Chertow GM; Paltiel AD; Owen WF; Lazarus JM
    Arch Intern Med; 1996 Jun; 156(12):1345-50. PubMed ID: 8651845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics of cancer screening: total costs and benefits in economic terms.
    Pedersen KM
    Eur J Cancer; 1994; 30A(6):879-84. PubMed ID: 7917552
    [No Abstract]   [Full Text] [Related]  

  • 14. History, development and future of cancer screening in Australia.
    Olver IN; Roder D
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluations of screening programs: a review of methods and results.
    Butler JR
    Clin Chim Acta; 2002 Jan; 315(1-2):31-40. PubMed ID: 11728408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The health economics of cancer screening in Germany: Which population-based interventions are cost-effective?].
    Schlander M; Cheng CY; Ran T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Dec; 61(12):1559-1568. PubMed ID: 30397723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for cancer: when to stop?: A practical guide and review of the evidence.
    Soung MC
    Med Clin North Am; 2015 Mar; 99(2):249-62. PubMed ID: 25700582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.